- Home
- WW vs IMAB Comparison
WW vs IMAB Comparison
Compare WW & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WW
- IMAB
- Stock Information
- Founded
- WW 1961
- IMAB 2014
- Country
- WW United States
- IMAB United States
- Employees
- WW N/A
- IMAB N/A
- Industry
- WW Other Consumer Services
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- WW Consumer Discretionary
- IMAB Health Care
- Exchange
- WW Nasdaq
- IMAB Nasdaq
- Market Cap
- WW 70.7M
- IMAB 83.8M
- IPO Year
- WW 2001
- IMAB 2020
- Fundamental
- Price
- WW $0.88
- IMAB $1.04
- Analyst Decision
- WW Buy
- IMAB Strong Buy
- Analyst Count
- WW 5
- IMAB 3
- Target Price
- WW $3.44
- IMAB $8.00
- AVG Volume (30 Days)
- WW 4.4M
- IMAB 411.1K
- Earning Date
- WW 11-06-2024
- IMAB 08-28-2024
- Dividend Yield
- WW N/A
- IMAB N/A
- EPS Growth
- WW N/A
- IMAB N/A
- EPS
- WW N/A
- IMAB N/A
- Revenue
- WW $807,465,000.00
- IMAB $3,313,984.00
- Revenue This Year
- WW N/A
- IMAB N/A
- Revenue Next Year
- WW N/A
- IMAB N/A
- P/E Ratio
- WW N/A
- IMAB N/A
- Revenue Growth
- WW N/A
- IMAB N/A
- 52 Week Low
- WW $0.67
- IMAB $0.99
- 52 Week High
- WW $9.77
- IMAB $2.54
- Technical
- Relative Strength Index (RSI)
- WW 41.85
- IMAB 39.28
- Support Level
- WW $0.81
- IMAB $1.02
- Resistance Level
- WW $1.24
- IMAB $1.13
- Average True Range (ATR)
- WW 0.12
- IMAB 0.08
- MACD
- WW -0.03
- IMAB -0.01
- Stochastic Oscillator
- WW 17.42
- IMAB 10.00
About WW WW International Inc.
WW International Inc is a provider of weight loss solutions. The firm offers its members access to in person workshops and digital solutions as a part of its weight loss and weight management programs. Its digital app provides members access to tools such as, trackers for food, water, activity, weight, content regarding behavioral techniques for building healthy habits and other related tools. Along with its in person workshops and digital solutions, the company also provides members who medically qualify access to clinicians who can prescribe weight management medications when clinically appropriate. The company generates majority of its revenue in the form of Subscription Revenue. Geographically, the company generates key revenue from North America and rest from International markets.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).